Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/parp-inhibitors-in-breast-cancer-latest-evidence-w3LkKTu1hE
References (48)
-
Viviana Masoud, Gilles Pagès (2017)
Targeted therapies in breast cancer: New challenges to fight against resistanceWorld Journal of Clinical Oncology, 8
-
R. Dent, G. Lindeman, M. Clemons, H. Wildiers, A. Chan, N. Mccarthy, C. Singer, E. Lowe, C. Watkins, J. Carmichael (2013)
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerBreast Cancer Research : BCR, 15
-
M. Dhawan, I. Bartelink, R. Aggarwal, Jim Leng, R. Kelley, M. Melisko, C. Ryan, S. Thomas, P. Munster (2017)
A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations.Journal of Clinical Oncology, 35
-
J. Bono, R. Ramanathan, L. Mina, R. Chugh, J. Glaspy, S. Rafii, S. Kaye, J. Sachdev, J. Heymach, David Smith, Joshua Henshaw, A. Herriott, M. Patterson, N. Curtin, L. Byers, Z. Wainberg (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.Cancer discovery, 7 6
-
J. Beumer, L. Appleman, H. Tawbi, R. Stoller, James Lee, Yan Lin, B. Kiesel, Jing Yu, A. Tan, C. Belani, H. Chew, Agustin Garcia, R. Morgan, A. Chen, V. Giranda, S. Shepherd, E. Chu, S. Puhalla (2014)
Outcome of BRCA 1/2-mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 26_suppl
-
R. Wilson, T. Evans, M. Middleton, L. Molife, J. Spicer, V. Diéras, P. Roxburgh, H. Giordano, S. Jaw-Tsai, S. Goble, R. Plummer (2017)
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumoursBritish Journal of Cancer, 116
-
B. Szekely, A. Silber, L. Pusztai (2017)
New Therapeutic Strategies for Triple-Negative Breast Cancer.Oncology, 31 2
-
J. O’Shaughnessy, L. Schwartzberg, M. Danso, K. Miller, H. Rugo, M. Neubauer, N. Robert, B. Hellerstedt, M. Saleh, P. Richards, J. Specht, D. Yardley, R. Carlson, R. Finn, Eric Charpentier, I. García-Ribas, E. Winer (2014)
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 34
-
J. Amé, C. Spenlehauer, G. Murcia (2004)
The PARP superfamilyBioEssays, 26
-
H. Han, V. Diéras, M. Friedlander, G. Somlo, B. Arun, H. Wildiers, B. Kaufman, J. Ayoub, M. Shah, David Burmedi, Q. Qin, J. Qian, V. Giranda, S. Shepherd (2015)
Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 28_suppl
-
J. Morales, Longshan Li, F. Fattah, Ying Dong, E. Bey, Malina Patel, Jinming Gao, D. Boothman (2014)
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Critical reviews in eukaryotic gene expression, 24 1
-
H. Roché, J. Blum, W. Eiermann, Y. Im, M. Martín, L. Mina, H. Rugo, F. Visco, Charlie Zhang, N. Lokker, D. Lounsbury, J. Litton (2015)
P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)Annals of Oncology, 26
-
J. Litton, M. Scoggins, D. Ramirez, R. Murthy, G. Whitman, K. Hess, B. Adrada, S. Moulder, C. Barcenas, V. Valero, D. Booser, J. Gomez, G. Mills, H. Piwnica-Worms, B. Arun (2016)
A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutationAnnals of Oncology, 27
-
H. Han, V. Diéras, M. Robson, M. Pálácova, P. Marcom, A. Jager, I. Bondarenko, D. Citrin, M. Campone, M. Telli, S. Domchek, M. Friedlander, B. Kaufman, C. Ratajczak, A. Coates, P. Bonnet, Q. Qin, J. Qian, V. Giranda, S. Shepherd, S. Isakoff, S. Puhalla (2017)
Abstract S2-05: Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) withBRCA1orBRCA2mutations and metastatic breast cancer: A randomized, phase 2 studyCancer Research, 77
-
K. Tryfonidis, J. Bogaerts, R. Martell, G. Sledge, J. Balmaña, M. Audeh, Angélique Deleersnijder, F. Favorito, S. Agarwal, G. Rizzetto, C. Messina, L. Slaets, T. Goulioti, A. Tutt, D. Cameron, N. Turner (2014)
A phase III randomized trial of niraparib versus physician’s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.Journal of Clinical Oncology, 32
-
R. Plummer, P. Stephens, Louiza Aissat-Daudigny, Anne Cambois, G. Moachon, P. Brown, M. Campone (2014)
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumorsCancer Chemotherapy and Pharmacology, 74
-
Yahiya Syed (2017)
Rucaparib: First Global ApprovalDrugs, 77
-
A. Tutt, B. Kaufman, R. Gelber, E. Fadden, C. Goessl, G. Viale, A. Arahmani, D. Fumagalli, H. Azim, Wenting Wu, Anna Grocholewicz, J. Costantino, P. Rastogi, J. Garber, C. Geyer (2015)
OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).Journal of Clinical Oncology, 33
-
G. Somlo, P. Frankel, B. Arun, Cynthia Ma, Agustin Garcia, T. Cigler, L. Cream, H. Harvey, J. Sparano, R. Nanda, H. Chew, T. Moynihan, L. Vahdat, M. Goetz, J. Beumer, A. Hurria, J. Mortimer, R. Piekarz, S. Sand, J. Herzog, Lily Tongeren, Katherine Ferry-Galow, A. Chen, C. Ruel, E. Newman, D. Gandara, J. Weitzel (2017)
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083Clinical Cancer Research, 23
-
Y. Drew, J. Ledermann, G. Hall, D. Rea, R. Glasspool, M. Highley, G. Jayson, J. Sludden, J. Murray, D. Jamieson, S. Halford, G. Acton, Zoe Backholer, R. Mangano, A. Boddy, N. Curtin, R. Plummer (2016)
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerBritish Journal of Cancer, 114
-
J. Balmaña, N. Tung, S. Isakoff, B. Graña, P. Ryan, C. Saura, E. Lowe, P. Frewer, E. Winer, J. Baselga, J. Garber (2014)
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
-
H. Rugo, O. Olopade, A. DeMichele, C. Yau, L. Veer, M. Buxton, M. Hogarth, N. Hylton, M. Paoloni, J. Perlmutter, W. Symmans, D. Yee, A. Chien, A. Wallace, H. Kaplan, J. Boughey, T. Haddad, K. Albain, Minetta Liu, C. Isaacs, Q. Khan, J. Lang, Rebecca Viscusi, L. Pusztai, S. Moulder, S. Chui, K. Kemmer, A. Elias, Kirsten Edmiston, D. Euhus, B. Haley, R. Nanda, D. Northfelt, D. Tripathy, W. Wood, C. Ewing, R. Schwab, J. Lyandres, S. Davis, G. Hirst, A. Sanil, D. Berry, L. Esserman (2016)
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.The New England journal of medicine, 375 1
-
A. Tutt, Mark Robson, Judy Garber, S. Domchek, M. Audeh, J. Weitzel, M. Friedlander, B. Arun, N. Loman, R. Schmutzler, Andrew Wardley, G. Mitchell, H. Earl, M. Wickens, J. Carmichael (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialThe Lancet, 376
-
E. Rodler, B. Kurland, M. Griffin, J. Gralow, P. Porter, R. Yeh, V. Gadi, Jamie Guenthoer, J. Beumer, L. Korde, S. Strychor, B. Kiesel, H. Linden, John Thompson, E. Swisher, X. Chai, S. Shepherd, V. Giranda, J. Specht (2016)
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast CancerClinical Cancer Research, 22
-
Fong Liu, K. Tewari (2016)
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP InhibitorsCurrent Treatment Options in Oncology, 17
-
S. Pahuja, J. Beumer, L. Appleman, H. Tawbi, R. Stoller, James Lee, Yan Lin, Fei Ding, Jing Yu, C. Belani, A. Chen, V. Giranda, S. Shepherd, E. Chu, S. Puhalla (2015)
A phase I study of veliparib (ABT-888) in combination with weekly carboplatin and paclitaxel in advanced solid malignancies and enriched for triple-negative breast cancer (TNBC).Journal of Clinical Oncology, 33
-
A. Patsouris, C. Vicier, L. Campion, W. Gouraud, M. Jimenez, V. Pezzella, A. Loehr, M. Raponi, I. Bièche, C. Callens, F. André (2017)
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.Journal of Clinical Oncology, 35
-
M. Robson, S. Im, E. Senkus, Bing-he Xu, S. Domchek, N. Masuda, S. Delaloge, Wei Li, N. Tung, A. Armstrong, Wenting Wu, C. Goessl, S. Runswick, P. Conte (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationThe New England Journal of Medicine, 377
-
Yuqiao Shen, F. Rehman, Ying Feng, J. Boshuizen, I. Bajrami, R. Elliott, B. Wang, C. Lord, L. Post, A. Ashworth (2013)
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair DeficiencyClinical Cancer Research, 19
-
M. Beau-Faller, J. Cadranel (2016)
Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.Annals of oncology : official journal of the European Society for Medical Oncology, 27 2
-
S. Domchek, Y. Bang, G. Coukos, K. Kobayashi, N. Baker, E. McMurtry, W. Song, B. Kaufman (2016)
MEDIOLA: A phase I/II, open-label trial of olaparib in combination with durvalumab (MEDI4736) in patients (pts) with advanced solid tumoursAnnals of Oncology, 27
-
J. Murai, Shar-yin Huang, B. Das, Amélie Renaud, Yiping Zhang, J. Doroshow, J. Ji, S. Takeda, Y. Pommier (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Cancer research, 72 21
-
N. Turner, M. Telli, H. Rugo, A. Mailliez, J. Ettl, E. Grischke, L. Mina, Judith Gelpí, P. Fasching, S. Hurvitz, A. Wardley, C. Chappey, W. Verret, A. Hannah, M. Robson (2017)
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).Journal of Clinical Oncology, 35
-
K. Miller, Y. Tong, David Jones, T. Walsh, M. Danso, Cynthia Ma, P. Silverman, M. King, S. Badve, S. Perkins (2015)
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.Journal of Clinical Oncology, 33
-
L. Wagner (2015)
Profile of veliparib and its potential in the treatment of solid tumorsOncoTargets and therapy, 8
-
B. Kaufman, R. Shapira-Frommer, R. Schmutzler, M. Audeh, M. Friedlander, J. Balmaña, G. Mitchell, G. Fried, S. Stemmer, A. Hubert, O. Rosengarten, M. Steiner, N. Loman, K. Bowen, A. Fielding, S. Domchek (2015)
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 3
-
R. Kristeleit, H. Burris, P. LoRusso, M. Patel, U. Asghar, F. El-Khouly, A. Calvert, J. Infante, J. Hilton, S. Tolaney, M. Kittaneh, H. Giordano, Jennifer Borrow, S. Jaw-Tsai, G. Shapiro (2014)
Phase 1/2 study of oral rucaparib: Final phase 1 results.Journal of Clinical Oncology, 32
-
C. Toms, N. Chopra, L. Houlton, Katy Jarman, L. Kilburn, J. Bliss, N. Turner (2016)
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)Annals of Oncology, 27
-
Lee Jm, J. Ledermann, Kohn Ec (2014)
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.Annals of oncology : official journal of the European Society for Medical Oncology, 25 1
-
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
-
X. Liu, Yan Shi, D. Maag, J. Palma, M. Patterson, P. Ellis, B. Surber, Damien Ready, N. Soni, U. Ladror, Allison Xu, R. Iyer, J. Harlan, L. Solomon, C. Donawho, T. Penning, Eric Johnson, A. Shoemaker (2011)
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP InhibitorClinical Cancer Research, 18
-
Amy Dréan, C. Lord, A. Ashworth (2016)
PARP inhibitor combination therapy.Critical reviews in oncology/hematology, 108
-
K. Dziadkowiec, Emilia Gasiorowska, E. Nowak-Markwitz, A. Jankowska (2016)
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targetingPrzegla̜d Menopauzalny = Menopause Review, 15
-
C. Geyer, J. O’Shaughnessy, M. Untch, W. Sikov, H. Rugo, M. McKee, J. Huober, M. Golshan, V. Giranda, G. Minckwitz, D. Maag, D. Sullivan, N. Wolmark, K. McIntyre, J. Lorenzo, O. Filho, P. Rastogi, W. Symmans, Xuan Liu, S. Loibl (2017)
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).Journal of Clinical Oncology, 35
-
R. Wesolowski, Meng Zhao, S. Geyer, M. Lustberg, E. Mrózek, R. Layman, E. Macrae, Jun Zhang, N. Hall, K. Schregel, Susan Ottman, Andrea Camp, J. Chalmers, E. Andreopoulou, M. Villalona-Calero, C. Shapiro, M. Knopp, M. Grever, B. Ramaswamy (2014)
Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).Journal of Clinical Oncology, 32
-
J. Litton, M. Scoggins, G. Whitman, C. Barcenas, S. Moulder, R. Murthy, Sausan Abouharb, B. Adrada, T. Helgason, Jill Schwartz-Gomez, E. Mittendorf, A. Thompson, B. Arun (2017)
A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345.Journal of Clinical Oncology, 35
-
P. Konstantinopoulos, K. Moore, J. Sachdev, M. Mita, S. Vinayak, Shelly Seward, V. Karantza, G. Aktan, Andrew Ferguson, D. Bobilev, U. Matulonis (2016)
Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).Journal of Clinical Oncology, 34
-
S. Sandhu, W. Schelman, G. Wilding, V. Moreno, R. Baird, S. Miranda, L. Hylands, R. Riisnaes, M. Forster, A. Omlin, N. Kreischer, K. Thway, H. Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, C. Toniatti, C. Carpenter, R. Iannone, S. Kaye, J. Bono, R. Wenham (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.The Lancet. Oncology, 14 9
- Publisher
- Springer Journals
- Copyright
- Copyright © 2017 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-017-0251-x
- Publisher site
- See Article on Publisher Site
Abstract
Purpose of Review Breast cancer treatment continues to inhibitors in breast cancers are encouraging in patients with evolve as targeted therapeutic strategies are developed for germline deleterious BRCA1/2 mutations, continued work is the various molecular subtypes of breast cancer. The PARP needed to elucidate their utility beyond the BRCA1/2-mutated inhibitors represent a novel targeted therapy for tumors with population as has been possible in ovarian cancer. defective homologous recombination DNA repair. These Additionally, defining the ideal population and setting for agents may become standard new treatment options for pa- combination treatment remains a challenge and has been lim- tients harboring BRCA1/2 mutations and show promise in ited by synergistic toxicities. BRCA1/2 wild-type patients with triple-negative breast can- cers, which are treated predominantly with traditional cytotox- . . Keywords PARP inhibitors Breast cancer treatment ic chemotherapy. This review will discuss the results of clin- . . Targeted therapeutic strategies BRCA1/2 mutations Breast ical trials of these agents in breast cancer as well as important cancer ongoing and anticipated trials. Recent Findings Recent reports support the use of olaparib monotherapy in BRCA1/2-mutated metastatic cancer. Results of PARP inhibitor combinations with chemotherapy Introduction have been mixed. The addition of veliparib failed to
Journal
Current Breast Cancer Reports – Springer Journals
Published: Jul 28, 2017